Document Type : Letter to the Editor


1 Neuroscience Research Group, Universal Scientific Education and Research Network, Tehran, Iran School of Medicine, Iran University of Medical Sciences, Tehran, Iran

2 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran




  1. Carnero CE, Correale J. Neuromyelitis optica spectrum disorders: From pathophysiology to therapeutic strategies. J Neuroinflammation 2021; 18(1): 208.
  2. Carnero CE, Rojas JI, Cristiano E, Marques VD, Flores-Rivera J, Lana-Peixoto M, et al. Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Mult Scler Relat Disord 2020; 45: 102428.
  3. Frampton JE. Eculizumab: A review in neuromyelitis optica spectrum disorder. Drugs 2020; 80(7): 719-27.
  4. Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021; 20(1): 60-7.
  5. Chamberlain JL, Huda S, Whittam DH, Matiello M, Morgan BP, Jacob A. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: A brief review. J Neurol 2021; 268(5): 1643-64.
  6. Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci USA 2012; 109(4): 1245-50.
  7. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381(7): 614-25.
  8. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol 2013; 12(6): 554-62.
  9. Digala L, Katyal N, Narula N, Govindarajan R. Eculizumab in the treatment of aquaporin-4 seronegative neuromyelitis optica spectrum disorder: a case report. Front Neurol 2021; 12: 660741.
  10. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48(14): 1631-42.